[EN] TREATMENT OF CNS DISEASES WITH SGC STIMULATORS<br/>[FR] TRAITEMENT DE MALADIES DU SNC AU MOYEN DE STIMULATEURS DE GCS
申请人:IRONWOOD PHARMACEUTICALS INC
公开号:WO2018089328A1
公开(公告)日:2018-05-17
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3',5'-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.